WO1994024144A3 - Enhanced triple-helix and double-helix formation with oligomers containing modified purines - Google Patents

Enhanced triple-helix and double-helix formation with oligomers containing modified purines Download PDF

Info

Publication number
WO1994024144A3
WO1994024144A3 PCT/US1994/004013 US9404013W WO9424144A3 WO 1994024144 A3 WO1994024144 A3 WO 1994024144A3 US 9404013 W US9404013 W US 9404013W WO 9424144 A3 WO9424144 A3 WO 9424144A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligomers
helix
double
triplexes
oligomers containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/004013
Other languages
French (fr)
Other versions
WO1994024144A2 (en
Inventor
Brian Froehler
Mark Matteucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to EP94914131A priority Critical patent/EP0695306A1/en
Priority to AU66320/94A priority patent/AU6632094A/en
Publication of WO1994024144A2 publication Critical patent/WO1994024144A2/en
Publication of WO1994024144A3 publication Critical patent/WO1994024144A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain 7-deaza-7-substituted purines or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used as pharmaceutical agents to treat various diseases such as those caused by viruses and can be used for diagnostic purposes in order to detect viruses or disease conditions.
PCT/US1994/004013 1993-04-19 1994-04-12 Enhanced triple-helix and double-helix formation with oligomers containing modified purines Ceased WO1994024144A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP94914131A EP0695306A1 (en) 1993-04-19 1994-04-12 Enhanced triple-helix and double-helix formation with oligomers containing modified purines
AU66320/94A AU6632094A (en) 1993-04-19 1994-04-12 Enhanced triple-helix and double-helix formation with oligomers containing modified purines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5069893A 1993-04-19 1993-04-19
US08/050,698 1993-04-19

Publications (2)

Publication Number Publication Date
WO1994024144A2 WO1994024144A2 (en) 1994-10-27
WO1994024144A3 true WO1994024144A3 (en) 1995-03-16

Family

ID=21966852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/004013 Ceased WO1994024144A2 (en) 1993-04-19 1994-04-12 Enhanced triple-helix and double-helix formation with oligomers containing modified purines

Country Status (3)

Country Link
EP (1) EP0695306A1 (en)
AU (1) AU6632094A (en)
WO (1) WO1994024144A2 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502177A (en) * 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
DE4438918A1 (en) * 1994-11-04 1996-05-09 Hoechst Ag Modified oligonucleotides, their preparation and their use
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
US5734040A (en) * 1996-03-21 1998-03-31 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
US6331617B1 (en) 1996-03-21 2001-12-18 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
US6274313B1 (en) 1996-03-21 2001-08-14 Pioneer-Hybrid International, Inc. Oligonucleotides with cationic phosphoramidate internucleoside linkages and methods of use
US6312897B1 (en) 1996-07-03 2001-11-06 President And Fellows Of Harvard College Template-directed interference footprinting of protein-adenine contacts
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
DE19842527A1 (en) * 1998-09-18 2000-03-23 Friedrich Schiller Uni Jena Bu Formation of a triple helix forming oligomer comprises searching for a cytosine and/or adenine-rich region of a double-stranded DNA
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
AU2001247414A1 (en) 2000-03-14 2001-09-24 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US7070933B2 (en) 2001-09-28 2006-07-04 Gen-Probe Incorporated Inversion probes
US7144868B2 (en) 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2005044835A1 (en) 2003-10-27 2005-05-19 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
EP1687321A1 (en) 2003-10-27 2006-08-09 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1680436A1 (en) 2003-10-27 2006-07-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn Structure and use of 5' phosphate oligonucleotides
WO2008157696A2 (en) 2007-06-19 2008-12-24 Stratos Genomics Inc. High throughput nucleic acid sequencing by expansion
WO2009035438A1 (en) * 2007-09-13 2009-03-19 Janos Borbely Polymeric nanoparticles by ion-ion interactions
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2987864B1 (en) 2009-01-29 2018-04-25 Stratos Genomics Inc. Method for detecting an analyte
US8343983B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted pyrazolo-pyrimidine compounds
US8586301B2 (en) 2010-06-30 2013-11-19 Stratos Genomics, Inc. Multiplexed identification of nucleic acid sequences
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US9212392B2 (en) 2012-09-25 2015-12-15 Exact Sciences Corporation Normalization of polymerase activity
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
EP2971154A4 (en) 2013-03-14 2017-03-01 Ibis Biosciences, Inc. Nucleic acid control panels
ES2859645T3 (en) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Neoplasia detection
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
EP3221327A1 (en) 2014-11-20 2017-09-27 Stratos Genomics, Inc. Nulceoside phosphoroamidate esters and derivatives thereof, use and synthesis thereof
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine, history and related antiviral uses
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
KR20250172724A (en) 2015-08-31 2025-12-09 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Detecting gastric neoplasm
KR20250073555A (en) 2015-10-30 2025-05-27 이그잭트 사이언시즈 코포레이션 Multiplex amplification detection assay and isolation and detection of dna from plasma
EP3904528A1 (en) 2015-11-16 2021-11-03 Stratos Genomics Inc. Dp04 polymerase variants
CN116064796A (en) 2016-05-05 2023-05-05 精密科学公司 Lung tumor detection by analysis of methylated DNA
JP7289264B2 (en) 2017-01-27 2023-06-09 エグザクト サイエンシーズ コーポレーション Detection of Colon Tumors by Analysis of Methylated DNA
WO2018204707A1 (en) 2017-05-04 2018-11-08 Stratos Genomics Inc. Dp04 polymerase variants
KR102626210B1 (en) 2017-12-07 2024-01-18 에모리 유니버시티 N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2018383610B2 (en) 2017-12-11 2024-09-12 F. Hoffmann-La Roche Ag DPO4 polymerase variants with improved accuracy
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US20230046033A1 (en) 2019-09-16 2023-02-16 Exact Sciences Corporation Structure and temperature-dependent flap endonuclease substrates
GB2605952A (en) * 2021-04-12 2022-10-26 Stealth Labels Biotech Ab Fluorescent nucleoside triphosphates
US20220403450A1 (en) 2021-06-03 2022-12-22 Illumina Software, Inc. Systems and methods for sequencing nucleotides using two optical channels
WO2023278781A1 (en) 2021-07-01 2023-01-05 Illumina, Inc. Device having horizontal nanochannel for nanopore sequencing
WO2023034079A1 (en) 2021-09-01 2023-03-09 Illumina Software, Inc. Amplitude modulation for accelerated base calling
AU2022349615A1 (en) 2021-09-22 2024-01-18 Illumina, Inc. Sequencing polynucleotides using nanopores
US12455277B2 (en) 2021-09-30 2025-10-28 Illumina, Inc. Isolation of cells in a nanopore sensor array
US20240319165A1 (en) 2021-11-15 2024-09-26 Illumina, Inc. Nanopore systems and methods of fabrication
US20230183799A1 (en) 2021-12-10 2023-06-15 Illumina, Inc. Parallel sample and index sequencing
WO2023175026A1 (en) 2022-03-15 2023-09-21 Illumina, Inc. Methods of determining sequence information
US20230357307A1 (en) 2022-05-04 2023-11-09 Illumina, Inc. Cleavable cyclic loop nucleotides for nanopore sequencing
WO2023239660A1 (en) 2022-06-07 2023-12-14 Illumina Software, Inc. Methods and systems for identifying gene variants
CA3260289A1 (en) 2022-07-07 2024-01-11 Illumina, Inc. Methods and systems for determining copy number variant genotypes
WO2024010809A2 (en) 2022-07-07 2024-01-11 Illumina Software, Inc. Methods and systems for detecting recombination events
WO2024073278A1 (en) 2022-09-26 2024-04-04 Illumina, Inc. Detecting and genotyping variable number tandem repeats
US12529677B2 (en) 2022-09-28 2026-01-20 Illumina, Inc. Fast pulsing for nanopore sensors
AU2024215884A1 (en) 2023-01-31 2024-10-03 Illumina, Inc. Copy number variant calling and recovery
CN119404254A (en) 2023-03-10 2025-02-07 因美纳有限公司 K-MER-based method for assembling polynucleotide sequences
EP4705506A1 (en) 2023-05-03 2026-03-11 Illumina, Inc. Controlled polynucleotide translocation in nanopore sequencing
EP4735635A1 (en) 2023-06-30 2026-05-06 Illumina, Inc. Systems and methods of sequencing polynucleotides with alternative scatterplots
EP4735636A1 (en) 2023-06-30 2026-05-06 Illumina, Inc. Systems and methods of sequencing polynucleotides with four labeled nucleotides
EP4735634A1 (en) 2023-06-30 2026-05-06 Illumina, Inc. Systems and methods of sequencing polynucleotides with modified bases
WO2025061942A1 (en) 2023-09-20 2025-03-27 Illumina, Inc. Sequencing error identification and correction
WO2025061922A1 (en) 2023-09-20 2025-03-27 Illumina, Inc. Methods for sequencing
US20250109433A1 (en) 2023-09-22 2025-04-03 Illumina, Inc. Macromolecule blocks for nanopore sequencing
WO2025072861A1 (en) 2023-09-29 2025-04-03 Illumina, Inc. Cleavable cyclic loop nucleotides for nanopore sequencing
WO2025072468A1 (en) 2023-09-29 2025-04-03 Illumina, Inc. Methods and systems for estimating copy numbers and detecting variants
WO2025072047A1 (en) 2023-09-29 2025-04-03 Illumina, Inc. Methods and systems for determining a cyp2a6 genotype
WO2025082960A1 (en) 2023-10-18 2025-04-24 F. Hoffmann-La Roche Ag Dpo4 polymerase variants with improved properties
WO2025149479A1 (en) 2024-01-12 2025-07-17 Roche Diagnostics Gmbh Synthesis of modified nucleoside triphosphates
WO2025149478A1 (en) 2024-01-12 2025-07-17 F. Hoffmann-La Roche Ag Compositions of modified nucleoside triphosphates
WO2025159980A1 (en) 2024-01-23 2025-07-31 Illumina, Inc. Ratchet-chelators as unique barcodes for nanopore sequencing
WO2025174659A1 (en) 2024-02-12 2025-08-21 Illumina, Inc. Net-zero current scheme for nanopore system
WO2025174660A1 (en) 2024-02-12 2025-08-21 Illumina, Inc. Recharging for nanopore system
WO2025183909A1 (en) 2024-03-01 2025-09-04 Illumina, Inc. Ribose-mediated cyclic loop opening for nanopore sequencing
WO2025184183A1 (en) 2024-03-01 2025-09-04 Illumina, Inc. Designer peptide cyclic loops for nanopore sequencing
WO2025190902A1 (en) 2024-03-13 2025-09-18 Illumina, Inc. Improving base calling quality scores
WO2025245014A1 (en) 2024-05-24 2025-11-27 Illumina, Inc. Nuclease assisted nanopore sequencing
WO2025250322A1 (en) 2024-05-31 2025-12-04 Illumina, Inc. Genotyping for tandem repeats
WO2025254714A1 (en) 2024-06-03 2025-12-11 Illumina, Inc. System and method for assembling a polynucleotide sequence
WO2026043922A1 (en) 2024-08-21 2026-02-26 Illumina, Inc. Modified nucleotides and related methods for nanopore sequencing
US20260085352A1 (en) 2024-09-26 2026-03-26 Illumina, Inc. Pulsed recharging for nanopore devices
WO2026072464A1 (en) 2024-09-27 2026-04-02 Illumina, Inc. Read mapping enhanced by spatial information

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3309358A (en) * 1965-09-20 1967-03-14 Upjohn Co 7-deazaadenine 2', 5'-and 3', 5'-dinucleoside phosphate and process therefor
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US3962211A (en) * 1975-01-13 1976-06-08 The University Of Utah 7-substituted nucleoside compounds
EP0021293A2 (en) * 1979-06-14 1981-01-07 The Wellcome Foundation Limited 4-Substituted thio-1-beta-D-ribofuranosylpyrazolo(3,4-D) pyrimidines, processes for their preparation, pharmaceutical formulations and medical uses
EP0057548A2 (en) * 1981-01-29 1982-08-11 Warner-Lambert Company 7-Beta-D-arabinofuranosyl-7H-pyrrolo(2,3-d)pyrimidine-4-amine 5'-phosphate compounds useful as antiviral agents, pharmaceutical compositions containing the compounds, and processes for producing the compounds
EP0251786A2 (en) * 1986-07-02 1988-01-07 E.I. Du Pont De Nemours And Company Alkynylamino-nucleotides
EP0286028A2 (en) * 1987-04-10 1988-10-12 Roche Diagnostics GmbH Derivatives of disazapurine nucleosides, process for their preparation and their use in the sequence analysis of nucleic acids and as antiviral agents
WO1989012060A1 (en) * 1988-06-06 1989-12-14 Steven Albert Benner Oligonucleotide analogs containing sulfur
WO1989012380A2 (en) * 1988-06-09 1989-12-28 Temple University Of The Commonwealth System Of Hi Therapeutic uses of 2',5'-oligoadenylate derivatives
WO1990003370A1 (en) * 1988-09-28 1990-04-05 Microprobe Corporation DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
EP0450102A1 (en) * 1989-10-26 1991-10-09 Yamasa Shoyu Kabushiki Kaisha Nucleoside derivative
WO1993003736A1 (en) * 1991-08-21 1993-03-04 Microprobe Corporation Cross-linking oligonucleotides for enzyme-mediated triple strand formation
WO1993009127A1 (en) * 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
WO1993012130A1 (en) * 1991-12-09 1993-06-24 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosines, isoster analogues and isoguanosine derivates and their use

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3309358A (en) * 1965-09-20 1967-03-14 Upjohn Co 7-deazaadenine 2', 5'-and 3', 5'-dinucleoside phosphate and process therefor
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US3962211A (en) * 1975-01-13 1976-06-08 The University Of Utah 7-substituted nucleoside compounds
EP0021293A2 (en) * 1979-06-14 1981-01-07 The Wellcome Foundation Limited 4-Substituted thio-1-beta-D-ribofuranosylpyrazolo(3,4-D) pyrimidines, processes for their preparation, pharmaceutical formulations and medical uses
EP0057548A2 (en) * 1981-01-29 1982-08-11 Warner-Lambert Company 7-Beta-D-arabinofuranosyl-7H-pyrrolo(2,3-d)pyrimidine-4-amine 5'-phosphate compounds useful as antiviral agents, pharmaceutical compositions containing the compounds, and processes for producing the compounds
EP0251786A2 (en) * 1986-07-02 1988-01-07 E.I. Du Pont De Nemours And Company Alkynylamino-nucleotides
EP0286028A2 (en) * 1987-04-10 1988-10-12 Roche Diagnostics GmbH Derivatives of disazapurine nucleosides, process for their preparation and their use in the sequence analysis of nucleic acids and as antiviral agents
WO1989012060A1 (en) * 1988-06-06 1989-12-14 Steven Albert Benner Oligonucleotide analogs containing sulfur
WO1989012380A2 (en) * 1988-06-09 1989-12-28 Temple University Of The Commonwealth System Of Hi Therapeutic uses of 2',5'-oligoadenylate derivatives
WO1990003370A1 (en) * 1988-09-28 1990-04-05 Microprobe Corporation DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
EP0450102A1 (en) * 1989-10-26 1991-10-09 Yamasa Shoyu Kabushiki Kaisha Nucleoside derivative
WO1993003736A1 (en) * 1991-08-21 1993-03-04 Microprobe Corporation Cross-linking oligonucleotides for enzyme-mediated triple strand formation
WO1993009127A1 (en) * 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
WO1993012130A1 (en) * 1991-12-09 1993-06-24 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosines, isoster analogues and isoguanosine derivates and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
F. SEELA: "Palindromic oligonucleotides containing 7-deaza-2'-deoxyguanosine", NUCLEIC ACIDS RES., vol. 14, 1986, pages 2319 - 32 *
F. SEELA: "Poly(adenylic acids) containing the antibiotic tubercidin", NUCLEIC ACIDS RES., vol. 10, 1982, pages 1389 - 97 *
J.F. MILLIGAN: "An anti-parallel triple helix motif with oligodeoxynucleotides containing 2'-deoxyguanosine and 7-deaza-2'-deoxy-xanthosine", NUCLEIC ACIDS RES., vol. 21, 25 January 1993 (1993-01-25), pages 327 - 33 *
M. IKEHARA: "Polynucleotides III.", CHEM. PHARM. BULL., vol. 14, 1966, pages 1338 - 46 *

Also Published As

Publication number Publication date
EP0695306A1 (en) 1996-02-07
AU6632094A (en) 1994-11-08
WO1994024144A2 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
US6369038B1 (en) Closed antisense and sense oligonucleotides and their applications
US5872105A (en) Single-stranded circular oligonucleotides useful for drug delivery
US5532130A (en) Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
US6372427B1 (en) Cooperative oligonucleotides
KR960704033A (en) Oligonucleotides with Activity against Humand Immunodeficiency Virus
WO2001002423A3 (en) 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith
HU9403788D0 (en) Self-stabilized oligonucleotides as therapeutic agents
US5849900A (en) Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
KR960701077A (en) Oligonucleotide Alkylphosphonate and Alkylphosphonothioate (ALIGLPHOSPHONATES AND ALKYLPHOSPHONOTHIOATES)
Praseuth et al. Double helices with parallel strands are formed by nuclease-resistant oligo-[α]-deoxynucleotides and oligo-[α]-deoxynucleotides covalently linked to an intercalating agent with complementary oligo-[β]-deoxynucleotides
EP0664833A1 (en) THERAPEUTIC ANTI-HIV OLIGONUCLEOTIDE AND MEDICINAL PRODUCT.
ATE460481T1 (en) METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICATION FOR THE THERAPY OF A TUMOR DISEASE
WO1999009154A3 (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
WO2007044727A2 (en) Pkr activation via hybridization chain reaction
GB2273932A (en) Stable oligonucleotides
HUT66828A (en) Single-stranded circular oligonucleotides
Bailly et al. The influence of the 2‐amino group of guanine on DNA conformation. Uranyl and DNase I probing of inosine/diaminopurine substituted DNA.
KR960704034A (en) Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and / or Multiplication of Infectious Disease Pathogens
Uhlmann et al. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression
WO1996023878A1 (en) Human immunodeficiency virus transcription inhibitors and methods of their use
JP2006514546A5 (en)
Yamakawa et al. Properties and anti-HIV activity of nicked dumbbell oligonucleotides
Frauendorf et al. Interaction of linear and folded modified antisense oligonucleotides with sequences containing secondary structure elements
WO2001068147A3 (en) Synthetic oligonucleotides as inducers of erythroid differentiation
Froehler et al. Enhanced triple-helix and double-helix formation with oligomers containing modified purines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1994914131

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994914131

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994914131

Country of ref document: EP